Steve, Andrew and I are in Philadelphia at the 21st Annual Scientific Conference of the American Association of Clinical Endocrinologists this week and we have been going full force to find the most intriguing information for you. In addition to covering the usual presentations and seminars, we have interviewed major thought leaders and will bring those to you in the next few weeks. As we spoke to many diabetes experts, the problem with patient follow-up and continuous motivation was a big problem, and anything that could be done to encourage adherence was seen as valuable. In addition, many patients live in areas that are not served by an endocrinologist or diabetes specialist and so getting them expert care is almost impossible. We had an opportunity to be with Dr. Ebenezer Nyenwe, FACE, University of Tennessee Medical Group, while he was discussing results of a trial on the benefits of using Telemedicine in the examination and treatment of patients. Check out The Virtual Examination Room – How New Technology Can Improve Diabetes Care to learn more.
There was also a lot of information at the sessions on the use of GLP-1 analogs and how they work to lower blood glucose. This week our current PharmD intern from the University of Colorado, Wael Diab, BSPharm, has reviewed the newest information focused on the increased secretion of insulin with his article GLP-1 Agonists: Increasing Effective Insulin Release.
Please answer this week’s poll: For your type 2 teenagers, after using metformin, your next medication choice is…
Check out this week’s “Test Your Diabetes Knowledge“ question!
Dave Joffe, Editor-in-chief